Submitted by Anonymous (not verified) on 11 September 2023 - 10:04
Human medicines European public assessment report (EPAR): Tremelimumab AstraZeneca, tremelimumab, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 20/02/2023, Revision: 1, Status: Authorised
Source: